Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OsteoDex in Relapsed/Refractory Multiple Myeloma
NCT06616389Phase 2Recruiting
- Sponsor
- DexTech Medical
- Start
- Nov 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of OsteoDex in multiple myeloma (MM), sponsored by DexTech Medical. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 14 weeks. Started Nov 2023; status: recruiting.
02
Drugs
OsteoDex
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06616389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616389.